Developer docs
API playgroundTry for free, no card

Search company profiles

DeciBio

Full company profile

uuid0009z67

Namestring
DeciBio
Legal namestring
DeciBio, LLC
Websiteurl
decibio.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

DeciBio is a precision medicine strategy consulting and market intelligence firm founded in 2009 and headquartered in Santa Monica, California. The firm delivers project-based consulting engagements spanning biomarker and diagnostics strategy, due diligence, go-to-market strategy, customer segmentation, competitive analysis, voice-of-customer research, and market landscaping and sizing. Its clients are primarily enterprise buyers across four verticals: Pharma & Biotech, Clinical Diagnostics, Research Tools, and Financial Services (including private equity and venture capital). DeciBio also publishes proprietary data products including quantitative market reports (e.g., 2026 IVD market report projecting $109B by 2030 and a 2025 proteomics tools report projecting ~$39B by 2030), DxBooks, Ad Boards, and expert transcripts, and operates a KOL/expert collaborator network with a 30% platform commission.

The firm goes to market through enterprise field sales supported by content-led demand generation: recurring newsletter franchises on AI, Digital Health and Informatics, and Liquid Biopsy, a thought-leadership blog, paid market reports, an active LinkedIn presence, and participation in industry events such as the J.P. Morgan Healthcare Conference. Pricing is project-based and quote-driven for consulting work, with data products sold as one-time licenses and an expert network monetized via marketplace commission. DeciBio has earned external recognition including Vault's Top Ranked Boutique Consulting (2023) and Great Place to Work's Best Places to Work (2025), and serves clients across the US, UK, Europe, Canada, APAC, and the Middle East.

The company's competitive advantage rests on a specialized talent bench that combines life-science depth with commercial insight, a growing proprietary content and data-asset library, and established KOL relationships that underpin primary research capabilities. As a private LLC with no disclosed funding history or institutional investors, DeciBio appears to operate as an independent, founder-led boutique that has sustained steady product, content, and geographic expansion through 2026.

Short descriptiontext

DeciBio is a precision medicine strategy consulting and market intelligence firm serving enterprise clients across Pharma & Biotech, Clinical Diagnostics, Research Tools, and Financial Services through project-based consulting, proprietary market reports, and a KOL expert network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWest Hollywood, United States
HQ citystring
West Hollywood
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
precision medicine consulting, life science market intelligence, biomarker strategy advisory, due diligence services, market research consulting
Industry1 code
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
Product category
Life Sciences / Precision Medicine Strategy Consulting
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Strategy Consulting Services
TypeProfessional Services
Description

DeciBio generates revenue primarily through project-based consulting engagements. Engagements include biomarker and diagnostics strategy, due diligence, go-to-market strategy, voice-of-customer research, competitive analysis, market landscaping and sizing, and customer segmentation. Projects vary in scope from targeted assessments to comprehensive market studies.

decibio.com
2Data Products and Market Reports
TypeOne Time License
Description

DeciBio sells data products including market reports (IVD market reports, proteomics tools market reports, oncology genomics trackers), Ad Boards, DxBooks, and transcripts. These are published research products available for purchase through their data platforms.

decibio.com
3KOL/Expert Network (Collaborator Model)
TypeMarketplace Commission
Description

DeciBio operates a collaborator/expert network where KOLs and industry experts contribute to consulting projects. The company charges collaborators a maximum commission of 30% on completed transactions for using the platform, suggesting a marketplace model for expert engagement.

decibio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Operations, Technology or R&D, Others
Pricing details1 tier
1Collaborator commission structure
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Maximum 30% commission charged to collaborators/experts on completed transactions for platform usage.

decibio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

DeciBio provides project-based strategy consulting and market intelligence services to firms in clinical diagnostics, life science research tools, pharma & biotech, and financial services. Its consulting capabilities span due diligence, biomarker and diagnostics strategy, go-to-market strategy, customer segmentation, voice-of-customer research, competitive analysis, and market landscaping/sizing. The firm also sells standalone data products — Market Reports, DxBooks, Ad Boards, and Transcripts — covering precision medicine markets such as IVD and proteomics tools.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • DeciBio-enabled client made rapid decision to proceed with $150M growth equity investment in oncology diagnostics provider
+1 more record
Product overview1 text field

DeciBio is a precision medicine strategy consulting firm offering a combination of consulting services and data products. The consulting services include market research (AdBoards, competitive analysis, market landscaping, KOL identification, surveys/trackers, voice-of-customer research), strategy consulting (biomarker and diagnostics strategy, customer segmentation, due diligence, go-to-market strategy, pricing strategy, revenue projection, target identification), and data analytics. The data products portfolio includes Market Reports providing quantitative market intelligence, DxBooks for diagnostic insights, Ad Boards for expert advisory services, and Transcripts of expert interviews. The company serves industries including clinical diagnostics, financial services, pharma and biotech, and research tools.

Product and service11 records
1Due Diligence Services
CategoryStrategy Consulting
Description

Comprehensive due diligence capabilities covering technology, market, customers, competitors, business model, regulatory strategy, and reimbursement assessment for life sciences investments. Targeted at financial sponsors and corporate investors evaluating precision medicine targets.

2Biomarker and Diagnostics Strategy
CategoryStrategy Consulting
Description

Expertise in biomarker discovery, companion diagnostic partner identification, IVD launch planning, and assay clinical journey integration for precision medicine. Targeted at pharma, biotech, and diagnostics companies developing precision medicine and CDx strategies.

3Go-to-Market Strategy
CategoryStrategy Consulting
Description

Strategy consulting service focused on execution tactics, coordination, and alignment across organizations for market entry. Targeted at life sciences companies commercializing precision medicine products.

4Customer Segmentation
CategoryStrategy Consulting
Description

Market research service analyzing customer needs, value propositions, decision-making drivers, and optimal customer targeting strategies for life sciences and precision medicine clients.

5Voice-of-Customer Research
CategoryMarket Research
Description

Primary research service conducting interviews and surveys with key stakeholders to gather market insights and customer feedback for precision medicine and life sciences clients.

6Competitive Analysis
CategoryMarket Research
Description

Market intelligence service profiling competitors, analyzing market positioning, and assessing competitive differentiation across precision medicine and life sciences markets.

7Market Landscaping and Sizing
CategoryMarket Research
Description

Quantitative market analysis including market sizing models, growth projections, and landscape assessments across precision medicine segments such as IVD, proteomics, and oncology genomics.

8Market Reports
CategoryData Product
Description

Quantitative market reports covering precision medicine segments including in vitro diagnostics, proteomics tools, and oncology genomics trackers. Available for purchase through DeciBio's data platforms as standalone one-time-license products.

9DxBooks
CategoryData Product
Description

Data product providing diagnostic and market intelligence information across precision medicine and clinical diagnostics markets.

10Ad Boards
CategoryData Product
Description

Advisory board research services connecting companies with key opinion leaders for strategic market insights on precision medicine topics.

11Transcripts
CategoryData Product
Description

Interview transcripts providing verbatim expert perspectives on precision medicine markets and technologies, available for purchase through DeciBio's data platform.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1ZS Associates
TypeBroad incumbent
Description

ZS is a large professional services firm serving pharma and biotech with strategy, sales, and marketing consulting — competes with DeciBio on commercial strategy and go-to-market engagements, though with a much broader portfolio and analytics-heavy delivery model.

TypeBroad incumbent
Description

Frost & Sullivan is a large-scale market intelligence and consulting firm producing syndicated reports and custom consulting across life sciences, diagnostics, and healthcare — competes with DeciBio on both data products and project-based consulting, though at much broader scope.

TypeDirect peer
Description

ClearView is a life sciences strategy consulting firm serving pharma, biotech, and medical device clients with commercial due diligence, market access, and portfolio strategy — directly comparable to DeciBio's pharma/biotech commercial due diligence and biomarker strategy offerings.

TypeBroad incumbent
Description

GlobalData is a large market intelligence and analytics platform covering healthcare, pharma, and medical devices with syndicated reports and consulting — directly competitive with DeciBio's market reports and due diligence data products at the high end of the market.

TypeBroad incumbent
Description

CRA's Life Sciences practice provides economic and strategy consulting, commercial due diligence, and litigation support to pharma, biotech, and diagnostics clients — a direct larger-scale competitor to DeciBio on enterprise consulting mandates, particularly for PE/VC commercial due diligence.

TypeDirect peer
Description

Health Advances is a boutique life science strategy consulting firm focused on commercial strategy, due diligence, and market assessment for pharma, biotech, diagnostics, and medtech clients — the most direct head-to-head peer to DeciBio in the precision medicine strategy space.

TypeEmerging player
Description

Definitive Healthcare provides a healthcare commercial intelligence platform with data on providers, diagnostics, and life sciences — an emerging data-product peer to DeciBio's DxBooks and market reports, though anchored in provider data rather than market/sizing data.

TypeEmerging player
Description

Roots Analysis is a market research firm publishing syndicated reports on life science and healthcare markets, including diagnostics, omics, and precision medicine — closely comparable to DeciBio's IVD, proteomics, and oncology genomics market reports business.

TypeDirect peer
Description

Back Bay is a life science-focused strategy and transaction advisory firm providing commercial due diligence, capital raising, and licensing support to pharma, biotech, and medtech clients — overlapping directly with DeciBio's financial services and pharma/biotech due diligence mandates.

TypeBroad incumbent
Description

L.E.K. is a large global strategy consulting firm with a substantial Life Sciences practice covering pharma, biotech, diagnostics, and medtech — competes with DeciBio for precision medicine commercial due diligence and strategy engagements but at materially larger scale and broader portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DeciBio

Life Sciences / Precision Medicine Strategy Consultingdecibio.com

DeciBio is a precision medicine strategy consulting and market intelligence firm serving enterprise clients across Pharma & Biotech, Clinical Diagnostics, Research Tools, and Financial Services through project-based consulting, proprietary market reports, and a KOL expert network.

What DeciBio does

DeciBio is a precision medicine strategy consulting and market intelligence firm founded in 2009 and headquartered in Santa Monica, California. The firm delivers project-based consulting engagements spanning biomarker and diagnostics strategy, due diligence, go-to-market strategy, customer segmentation, competitive analysis, voice-of-customer research, and market landscaping and sizing. Its clients are primarily enterprise buyers across four verticals: Pharma & Biotech, Clinical Diagnostics, Research Tools, and Financial Services (including private equity and venture capital). DeciBio also publishes proprietary data products including quantitative market reports (e.g., 2026 IVD market report projecting $109B by 2030 and a 2025 proteomics tools report projecting ~$39B by 2030), DxBooks, Ad Boards, and expert transcripts, and operates a KOL/expert collaborator network with a 30% platform commission.

The firm goes to market through enterprise field sales supported by content-led demand generation: recurring newsletter franchises on AI, Digital Health and Informatics, and Liquid Biopsy, a thought-leadership blog, paid market reports, an active LinkedIn presence, and participation in industry events such as the J.P. Morgan Healthcare Conference. Pricing is project-based and quote-driven for consulting work, with data products sold as one-time licenses and an expert network monetized via marketplace commission. DeciBio has earned external recognition including Vault's Top Ranked Boutique Consulting (2023) and Great Place to Work's Best Places to Work (2025), and serves clients across the US, UK, Europe, Canada, APAC, and the Middle East.

The company's competitive advantage rests on a specialized talent bench that combines life-science depth with commercial insight, a growing proprietary content and data-asset library, and established KOL relationships that underpin primary research capabilities. As a private LLC with no disclosed funding history or institutional investors, DeciBio appears to operate as an independent, founder-led boutique that has sustained steady product, content, and geographic expansion through 2026.

DeciBio firmographics

Firmographics
Name
DeciBio
Legal name
DeciBio, LLC
Website
https://decibio.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
51–100 employees
Short description
DeciBio is a precision medicine strategy consulting and market intelligence firm serving enterprise clients across Pharma & Biotech, Clinical Diagnostics, Research Tools, and Financial Services through project-based consulting, proprietary market reports, and a KOL expert network.
Ownership category
akta.pro rank

Where DeciBio is headquartered

Location

Headquarters

HQ city
West Hollywood
HQ country
United States
HQ region
North America

Markets served

DeciBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Marketing or Sales, Operations, Technology or R&D, Others

Revenue model

  1. Strategy Consulting Services: DeciBio generates revenue primarily through project-based consulting engagements. Engagements include biomarker and diagnostics strategy, due diligence, go-to-market strategy, voice-of-customer research, competitive analysis, market landscaping and sizing, and customer segmentation. Projects vary in scope from targeted assessments to comprehensive market studies.
  2. Data Products and Market Reports: DeciBio sells data products including market reports (IVD market reports, proteomics tools market reports, oncology genomics trackers), Ad Boards, DxBooks, and transcripts. These are published research products available for purchase through their data platforms.
  3. KOL/Expert Network (Collaborator Model): DeciBio operates a collaborator/expert network where KOLs and industry experts contribute to consulting projects. The company charges collaborators a maximum commission of 30% on completed transactions for using the platform, suggesting a marketplace model for expert engagement.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goCollaborator commission structure

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

DeciBio product offering

Product offering

Core offering

DeciBio provides project-based strategy consulting and market intelligence services to firms in clinical diagnostics, life science research tools, pharma & biotech, and financial services. Its consulting capabilities span due diligence, biomarker and diagnostics strategy, go-to-market strategy, customer segmentation, voice-of-customer research, competitive analysis, and market landscaping/sizing. The firm also sells standalone data products — Market Reports, DxBooks, Ad Boards, and Transcripts — covering precision medicine markets such as IVD and proteomics tools.

Product overview

DeciBio is a precision medicine strategy consulting firm offering a combination of consulting services and data products. The consulting services include market research (AdBoards, competitive analysis, market landscaping, KOL identification, surveys/trackers, voice-of-customer research), strategy consulting (biomarker and diagnostics strategy, customer segmentation, due diligence, go-to-market strategy, pricing strategy, revenue projection, target identification), and data analytics. The data products portfolio includes Market Reports providing quantitative market intelligence, DxBooks for diagnostic insights, Ad Boards for expert advisory services, and Transcripts of expert interviews. The company serves industries including clinical diagnostics, financial services, pharma and biotech, and research tools.

Differentiator

Problem solved

Functional benefit

Products and services

  • Due Diligence Services Comprehensive due diligence capabilities covering technology, market, customers, competitors, business model, regulatory strategy, and reimbursement assessment for life sciences investments. Targeted at financial sponsors and corporate investors evaluating precision medicine targets.
  • Biomarker and Diagnostics Strategy Expertise in biomarker discovery, companion diagnostic partner identification, IVD launch planning, and assay clinical journey integration for precision medicine. Targeted at pharma, biotech, and diagnostics companies developing precision medicine and CDx strategies.
  • Go-to-Market Strategy Strategy consulting service focused on execution tactics, coordination, and alignment across organizations for market entry. Targeted at life sciences companies commercializing precision medicine products.
  • Customer Segmentation Market research service analyzing customer needs, value propositions, decision-making drivers, and optimal customer targeting strategies for life sciences and precision medicine clients.
  • Voice-of-Customer Research Primary research service conducting interviews and surveys with key stakeholders to gather market insights and customer feedback for precision medicine and life sciences clients.
  • Competitive Analysis Market intelligence service profiling competitors, analyzing market positioning, and assessing competitive differentiation across precision medicine and life sciences markets.
  • Market Landscaping and Sizing Quantitative market analysis including market sizing models, growth projections, and landscape assessments across precision medicine segments such as IVD, proteomics, and oncology genomics.
  • Market Reports Quantitative market reports covering precision medicine segments including in vitro diagnostics, proteomics tools, and oncology genomics trackers. Available for purchase through DeciBio's data platforms as standalone one-time-license products.
  • DxBooks Data product providing diagnostic and market intelligence information across precision medicine and clinical diagnostics markets.
  • Ad Boards Advisory board research services connecting companies with key opinion leaders for strategic market insights on precision medicine topics.
  • Transcripts Interview transcripts providing verbatim expert perspectives on precision medicine markets and technologies, available for purchase through DeciBio's data platform.

Quantifiable outcome

  • DeciBio-enabled client made rapid decision to proceed with $150M growth equity investment in oncology diagnostics provider
  • +1 more outcomes

Companies that use DeciBio

Customer profile

Segments4 records

Ideal customer profiles4 records

DeciBio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

DeciBio partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

DeciBio competitors and assessment

Company assessment

Broad incumbents

  • ZS Associates: ZS is a large professional services firm serving pharma and biotech with strategy, sales, and marketing consulting — competes with DeciBio on commercial strategy and go-to-market engagements, though with a much broader portfolio and analytics-heavy delivery model.
  • Frost & Sullivan: Frost & Sullivan is a large-scale market intelligence and consulting firm producing syndicated reports and custom consulting across life sciences, diagnostics, and healthcare — competes with DeciBio on both data products and project-based consulting, though at much broader scope.
  • GlobalData: GlobalData is a large market intelligence and analytics platform covering healthcare, pharma, and medical devices with syndicated reports and consulting — directly competitive with DeciBio's market reports and due diligence data products at the high end of the market.
  • Charles River Associates (Life Sciences): CRA's Life Sciences practice provides economic and strategy consulting, commercial due diligence, and litigation support to pharma, biotech, and diagnostics clients — a direct larger-scale competitor to DeciBio on enterprise consulting mandates, particularly for PE/VC commercial due diligence.
  • L.E.K. Consulting: L.E.K. is a large global strategy consulting firm with a substantial Life Sciences practice covering pharma, biotech, diagnostics, and medtech — competes with DeciBio for precision medicine commercial due diligence and strategy engagements but at materially larger scale and broader portfolio.

Direct peers

  • ClearView Healthcare Partners: ClearView is a life sciences strategy consulting firm serving pharma, biotech, and medical device clients with commercial due diligence, market access, and portfolio strategy — directly comparable to DeciBio's pharma/biotech commercial due diligence and biomarker strategy offerings.
  • Health Advances: Health Advances is a boutique life science strategy consulting firm focused on commercial strategy, due diligence, and market assessment for pharma, biotech, diagnostics, and medtech clients — the most direct head-to-head peer to DeciBio in the precision medicine strategy space.
  • Back Bay Life Science Advisors: Back Bay is a life science-focused strategy and transaction advisory firm providing commercial due diligence, capital raising, and licensing support to pharma, biotech, and medtech clients — overlapping directly with DeciBio's financial services and pharma/biotech due diligence mandates.

Emerging players

  • Definitive Healthcare: Definitive Healthcare provides a healthcare commercial intelligence platform with data on providers, diagnostics, and life sciences — an emerging data-product peer to DeciBio's DxBooks and market reports, though anchored in provider data rather than market/sizing data.
  • Roots Analysis: Roots Analysis is a market research firm publishing syndicated reports on life science and healthcare markets, including diagnostics, omics, and precision medicine — closely comparable to DeciBio's IVD, proteomics, and oncology genomics market reports business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

DeciBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DeciBio leadership team

Management profile

Number of profiles

Profiles2 records

DeciBio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DeciBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeciBio

What does DeciBio do?

DeciBio provides project-based strategy consulting and market intelligence services to firms in clinical diagnostics, life science research tools, pharma & biotech, and financial services. Its consulting capabilities span due diligence, biomarker and diagnostics strategy, go-to-market strategy, customer segmentation, voice-of-customer research, competitive analysis, and market landscaping/sizing. The firm also sells standalone data products — Market Reports, DxBooks, Ad Boards, and Transcripts — covering precision medicine markets such as IVD and proteomics tools.

Is DeciBio a public or private company?

DeciBio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DeciBio founded?

DeciBio was founded in 2009. It employs 51 to 100 people.

Where is DeciBio based?

DeciBio is headquartered in West Hollywood, United States, in the North America region.

How does DeciBio make money?

Three revenue lines are on record. Strategy Consulting Services are the primary driver. The others are data Products and Market Reports and KOL/Expert Network (Collaborator Model).

Who are DeciBio's main competitors?

Broad incumbents on record are ZS Associates, Frost & Sullivan, GlobalData, Charles River Associates (Life Sciences) and L.E.K. Consulting. Direct peers are ClearView Healthcare Partners, Health Advances and Back Bay Life Science Advisors. Emerging players are Definitive Healthcare and Roots Analysis.

Does DeciBio have an API?

No public API is recorded for DeciBio.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogWorldwide Digital & Computational Pathology Market Forecasted to Grow at 12% p.a., Reaching $2.1B by 2031 – Market Report by DeciBio Consulting LLCDeciBio Consulting's market report forecasts the global digital and computational pathology market to reach $2.1 billion by 2031, growing at a 12% annual rate. The report highlights biopharma as the largest customer segment and notes regulatory fragmentation and reimbursement limitations as key moderators.LinkedInJellagen Partners with Royal Biologics for Regenerative Medicine BreakthroughDeciBio's Carl Schoellhammer conducted a Q&A with Codexis SVP Britton Jimenez on the evolving manufacturing landscape for oligonucleotide therapeutics, discussing challenges in scaling RNA-based medicines. The interview covers topics including traditional synthesis limitations, RNAi commercial-scale bottlenecks, and how enzymatic approaches could improve efficiency and sustainability. The article references a link to the full Q&A discussing manufacturing innovation's role in advancing oligonucleotide therapeutics.DeciBioWorldwide In Vitro Diagnostics (IVD) market forecasted to grow at 4% p.a., reaching $109B by 2030 – Market Report by DeciBio Consulting LLCDeciBio Consulting LLC forecasts that the global in vitro diagnostics (IVD) market will grow at a 4% annual rate, reaching $109 billion by 2030. This expansion is driven by increased diagnostic access, new therapies requiring ongoing testing, and emerging technologies like liquid biopsy, though growth faces headwinds from reimbursement pressures and workforce shortages.YahooWorldwide In Vitro Diagnostics (IVD) Market Forecasted to Grow at 4% p.a., Reaching $109B by 2030 – Market Report by DeciBio Consulting LLCDeciBio Consulting LLC released a market report forecasting the global In Vitro Diagnostics (IVD) market to reach $109 billion by 2030, growing at a compound annual growth rate of 4%. The expansion is attributed to increased diagnostic access, the development of new therapies requiring ongoing testing, and the adoption of emerging technologies like liquid biopsy. Key industry players profiled in the report include Abbott, Roche, Danaher, and Siemens Healthineers.Business Wire BlogWorldwide In Vitro Diagnostics (IVD) Market Forecasted to Grow at 4% p.a., Reaching $109B by 2030 – Market Report by DeciBio Consulting LLCDeciBio Consulting LLC published a comprehensive market report projecting the global in vitro diagnostics market to reach $109 billion by 2030, growing at a compound annual growth rate of 4% during 2025–2030. The report identifies key growth drivers including increasing global access to diagnostics, new therapies requiring ongoing testing, and emerging technologies such as liquid biopsy and digital pathology. Market moderators cited in the report include downward pressure on reimbursement rates, workforce shortages in laboratory medicine and pathology, and high switching costs that limit new market entrants.DeciBioBeyond the Hype: Top 5 Life Science Tech Trends Set to Define 2026DeciBio outlines key trends for the 2026 life sciences sector, emphasizing a strategic shift from technological discovery to clinical integration and reimbursement. The report highlights advancements in next-generation sequencing, spatial biology, liquid biopsy, and AI-driven pathology as critical areas for commercial validation. It identifies major industry players such as Illumina, ThermoFisher, and Natera as active participants in this consolidation and expansion phase.Business Wire BlogPharma R&D Services Market Forecast to Grow at 5% p.a., Reaching ~$129B by 2029 – Market Report by DeciBio Consulting LLCDeciBio Consulting released its first Pharma R&D Services Market Report, forecasting the global market to reach approximately $129 billion by 2029, growing at a 5% CAGR from $101 billion in 2024. The report highlights that about 50% of pharma's $300 billion R&D investment in 2024 went to external partners, with growth driven by complex therapeutic modalities and AI, though moderated by patent expirations and geopolitical tensions.DeciBioPharma R&D Services Market Forecast to Grow at 5% p.a., Reaching ~$129B by 2029 – Market Report by DeciBio Consulting LLCDeciBio Consulting LLC announced the publication of its first edition market report forecasting the global pharma R&D services market to reach approximately $129 billion by 2029, growing at a 5% CAGR. The report highlights that external partners handled roughly 50% of pharmaceutical companies' R&D investments in 2024, driven by the complexity of new therapeutic modalities and the need for specialized expertise. Key market players profiled include major contract research organizations such as Charles River Laboratories, ICON, IQVIA, Labcorp, PPD, Syneos Health, WuXi AppTec, and Parexel.Cellandgene2025 Forecast For Advanced TherapiesDeciBio Consulting forecasts that oligonucleotides will continue their strong commercial growth in 2025, while mRNA technologies face a period of refinement and strategic reassessment following pandemic-era volatility. The advanced therapies sector is expected to see significant consolidation and investment in bioprocessing advancements, particularly within cell therapies and AAV gene therapies, as companies address manufacturing scale-up challenges.DeciBioRadiomics: The Intersection of Modern Deep Learning and Clinical ImagingIn an interview with Onc.AI CEO Akshay Nanduri, DeciBio Consulting discussed radiomics, defined as extracting quantitative imaging features from CT, MRI, PET-CT or ultrasound scans to predict or prognosticate disease. Nanduri cited a rise in radiomics research from 94 studies in 2016 to over 3,100 in 2023, and noted biopharma uses it for patient enrichment, screening and trial analysis. Onc.AI, a Series A company with roughly $30 million, plans to launch its first product for medical oncologists.